UNSPSC 51371804: Piritramide

This classification denotes an opioid analgesic, narcotic, and isonipecotic acid with the molecular formula C27H34N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4RP92LYZ2F, chemically known as 2,2-diphenyl-4-(4-piperidino-4-carbamoylpiperidino)butyronitrile but generally known as piritramide, which bears US NIH Compound Identifier 9331. European Medicines Agency schedules Piritramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09920MIG.

UNSPSC 51371804 Piritramide is a Commodity code that does not align with the recent state and local solicitations tagged under it. The three opportunities posted since April 2026 center on naloxone and drug-deactivation systems procurement (Seminole County, Florida), pharmacy benefit management and direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations address piritramide, a synthetic opioid analgesic with narrow clinical use in anesthesia and acute pain management. The code shows minimal relevant recent activity for state and local government procurement of piritramide itself.

The geographic activity reflected in these mismatched records spans Florida, Texas, and Minnesota through county health departments, state HHS agencies, and multi-state cooperative purchasing consortia. The issuing bodies include single counties (Seminole County), state health commissions, and cooperative purchasing alliances serving multiple states. If piritramide procurement does occur at the state and local level, it would likely flow through these same institutional channels as part of broader pharmaceutical supply agreements rather than as standalone solicitations. The absence of dedicated piritramide opportunities in recent postings suggests either very low procurement volume under this specific code or systematic misclassification of piritramide purchases under higher-level pharmaceutical family or class codes.